Maxim Group Maintains 'Hold' Rating on Reviva Pharmaceuticals Stock

Wall Street analysts weigh in on the pharmaceutical company's outlook.

Apr. 8, 2026 at 1:54pm

Got story updates? Submit your updates here. ›

Investment firm Maxim Group has maintained a 'hold' rating on the stock of Reviva Pharmaceuticals (NASDAQ: RVPH), according to a new research note. The note comes amid a mix of analyst opinions on the company, with some firms issuing 'buy' ratings while others have assigned 'sell' recommendations.

Why it matters

Reviva Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription drug products. Analyst ratings and price targets can significantly impact investor sentiment and the stock's performance, so the mixed views from Wall Street provide insight into the company's current standing and future prospects.

The details

In the research note, Maxim Group reiterated its 'hold' rating on Reviva Pharmaceuticals. Other analysts have issued a range of ratings, with Chardan Capital and HC Wainwright maintaining 'buy' recommendations, while Wall Street Zen and D. Boral Capital have assigned 'sell' ratings. The analysts' price targets for Reviva's stock also vary widely, from $40 to $80.

  • Maxim Group issued its research note on Reviva Pharmaceuticals on April 8, 2026.
  • Wall Street Zen raised its rating to 'sell' on March 14, 2026.
  • Chardan Capital reissued a 'buy' rating and $40 price target on January 5, 2026.
  • Weiss Ratings maintained a 'sell (e+)' rating on January 22, 2026.
  • HC Wainwright reiterated a 'buy' rating and $80 price target on December 23, 2025.

The players

Maxim Group

An investment firm that provides research coverage and ratings on Reviva Pharmaceuticals.

Wall Street Zen

An investment research firm that covers Reviva Pharmaceuticals and has assigned a 'sell' rating.

Chardan Capital

An investment bank that covers Reviva Pharmaceuticals and has a 'buy' rating with a $40 price target.

Weiss Ratings

A financial research firm that has maintained a 'sell (e+)' rating on Reviva Pharmaceuticals.

HC Wainwright

An investment bank that covers Reviva Pharmaceuticals and has a 'buy' rating with an $80 price target.

Got photos? Submit your photos here. ›

The takeaway

The mixed analyst opinions on Reviva Pharmaceuticals highlight the uncertainty surrounding the company's prospects, with some firms seeing upside potential while others are more cautious. Investors will likely continue to closely monitor the company's progress and any updates from the analyst community.